Blood Testing Market Size, Trends, and Key Insights to 2033

The blood testing market was valued at USD 94.07 billion in 2024 and is expected to grow from USD 102.02 billion in 2025 to reach USD 178.15 billion by 2033, expanding at a CAGR of 7.05% during the forecast period (2025–2033). Rising cases of chronic diseases such as diabetes, cardiovascular conditions, and cancer, combined with growing adoption of home-based testing solutions, are driving this market forward. Blood testing is an essential diagnostic tool in modern healthcare, helping doctors track organ function, detect pathogens, evaluate treatment response, and monitor overall health.

📥 Download Sample Report

Market Drivers

Increasing Prevalence of Chronic Diseases

One of the major growth drivers of the blood testing market is the rising burden of chronic illnesses. According to the World Health Organization (WHO), chronic diseases are responsible for nearly 60% of all deaths globally, with cardiovascular diseases alone causing 17.9 million deaths annually. Regular blood testing is crucial for early detection and management of these conditions. For instance, patients with diabetes require continuous monitoring of blood glucose levels, fueling the demand for glucose testing kits and devices. Similarly, cancer diagnosis and treatment often rely on blood-based biomarkers to assess disease progression and treatment effectiveness. Personalized medicine, which leverages these biomarkers to create tailored therapies, further strengthens the need for advanced blood testing technologies.

Technological Innovations in Blood Testing

Advancements such as liquid biopsy for non-invasive cancer detection and continuous glucose monitors have transformed diagnostics. These innovations offer faster, less invasive, and more accurate testing, making it easier to detect diseases at earlier stages. The convenience of point-of-care devices and digital health integration is also propelling adoption in both hospital and home settings.

Growing Demand for Home-Based Testing

The COVID-19 pandemic accelerated the adoption of home-based blood testing kits. Companies like Everlywell and LetsGetChecked provide at-home collection solutions, which patients can send to labs for analysis. This model ensures safety, convenience, and proactive health monitoring. Consumers are increasingly embracing preventive healthcare, using home kits for cholesterol levels, hormone balance, and diabetes monitoring. With digital health apps enabling real-time results and telehealth consultations, this segment is expected to witness rapid growth.

Market Restraints

Despite strong growth drivers, high costs and regulatory hurdles remain barriers. Advanced testing technologies such as molecular and genetic assays can be expensive, limiting accessibility for many patients. Additionally, stringent approval processes from regulatory agencies like the FDA and EMA can delay product launches and increase compliance costs. These challenges are especially difficult for smaller companies looking to expand globally.

Regional Insights

North America Leads the Market

North America holds the largest market share, supported by robust healthcare infrastructure, high awareness, and the presence of leading players. Rising prevalence of chronic diseases, growing plasma donation initiatives, and early adoption of innovative technologies drive the region’s dominance. For example, prostate-specific antigen (PSA) testing is widely recommended in the U.S. for early detection of prostate cancer, fueling consistent demand.

Europe: Strong Second Position

Europe ranks as the second-largest market, driven by a strong healthcare system, increasing chronic disease prevalence, and investments in healthcare innovation. Government-funded programs such as Horizon 2020 are boosting research and adoption of advanced diagnostic tools.

Asia-Pacific: Fastest Growing Region

Asia-Pacific is projected to record the highest CAGR through 2033. Rapid healthcare advancements, a rising patient population, and increased investment in diagnostics are fueling regional expansion. Growing awareness of preventive healthcare and adoption of home-based testing also contribute to this growth.

Test Type and End-User Insights

• Glucose testing dominates the test type segment due to the global rise in diabetes cases and demand for continuous monitoring.
• Hospitals lead the end-user segment, as they perform a wide range of tests, manage blood donations, and support organ transplants with advanced technologies like nucleic acid testing.

Key Players

Prominent companies shaping the global blood testing market include:

• Abbott Diagnostics
• Bio-Rad Laboratories Inc.
• Roche Diagnostics
• Quest Diagnostics
• Danaher Corporation
• Becton Dickinson & Company
• BioMérieux S.A.
• Siemens Healthcare
• Trinity Biotech PLC.
• Grifols S.A.
• Hologic Inc.
• B. Braun Melsungen AG

Recent developments highlight innovation and funding activity. In July 2024, Truvian Health secured USD 74 million to advance FDA clearance for its next-gen testing platform. In March 2024, Babson Diagnostics launched its BetterWayâ„¢ blood testing service in partnership with retail chains in Texas, making testing more convenient and accessible.

Conclusion

The blood testing market is poised for steady growth, supported by the increasing prevalence of chronic diseases, technological innovation, and rising demand for home-based diagnostics. While cost and regulatory challenges persist, opportunities in preventive and personalized healthcare are expected to create strong growth potential for industry players.

About Us:

Straits Research is a leading market intelligence and consulting firm offering actionable insights and strategic guidance to businesses across industries. Our in-depth reports help organizations make informed decisions and stay ahead in competitive markets.

Contact Us:

For inquiries, reach out to us at Straits Research.